PDF herunterladen
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(09): 588-591
DOI: 10.1590/0004-282X20180083
Article

Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis

Perfil sorológico do vírus John Cunningham (JCV) em pacientes com esclerose múltipla
Luciana Prats Branco
1   Universidade Metropolitana de Santos, Departamento de Neurologia, São Paulo SP, Brasil
,
Tarso Adoni
2   Hospital Sírio Libanês de São Paulo, Departamento de Neurologia, São Paulo SP, Brasil
,
Samira Luisa Apostolos-Pereira
3   Universidade de São Paulo, Departamento de Neurologia, São Paulo SP, Brasil
,
Joseph Bruno Bidin Brooks
1   Universidade Metropolitana de Santos, Departamento de Neurologia, São Paulo SP, Brasil
,
Eber Castro Correa
4   Clínica de Neurologia e Endocrinologia, Departamento de Neurologia, Brasília DF, Brasil
,
Carlos Augusto Damasceno
5   Universidade Federal de Juiz de Fora, Departamento de Neurologia, Juiz de Fora MG, Brasil
,
Audred Cristina Biondo Eboni
6   Universidade da Região de Joinville, Departamento de Neurologia, Joinville SC, Brasil
,
Leticia Fezer
7   Santa Casa da Misericórdia do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil
,
Paulo Diniz da Gama
8   Pontificia Universidade Católica Sorocaba, Departamento de Neurologia, Sorocaba SP, Brasil
,
Marcus Vinicius Magno Goncalves
6   Universidade da Região de Joinville, Departamento de Neurologia, Joinville SC, Brasil
,
Sidney Gomes
9   Hospital Beneficencia Portuguesa, Departamento de Neurologia, São Paulo SP, Brasil
10   Hospital Paulistano, Departamento de Neurologia, São Paulo SP, Brasil
,
Anderson Kuntz Grzesiuk
11   Clínica Neurológica, Cuiabá MT, Brasil
,
Maria Fernanda Mendes
3   Universidade de São Paulo, Departamento de Neurologia, São Paulo SP, Brasil
,
Rogerio Rizo Morales
12   Universidade Federal de Uberlandia, Departamento de Neurologia, Uberlândia MG, Brasil
,
Andre Muniz
13   Hospital da Bahia, Departamento de Neurologia, Salvador BA, Brasil
,
Monica Fiuza Koncke Parolin
14   Clínica Neurológica, Curitiba PR, Brasil
,
Maria Lucia Vellutini Pimentel
7   Santa Casa da Misericórdia do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil
,
Marlise de Castro Ribeiro
15   Universidade Federal de Ciências da Saúde de Porto Alegre, Departamento de Neurologia, Porto Alegre RS, Brasil
,
Gutemberg Augusto Cruz dos Santos
16   Universidade Estacio de Sá, Departamento de Neurologia, Rio de Janeiro RJ, Brasil
,
Henry Koiti Sato
17   Instituto de Neurologia de Curitiba, Departamento de Neurologia, Curitiba PR, Brasil
,
Simone Batista Scherpenhuijzen
18   Universidade Federal do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil
,
Claudio Scorcine
1   Universidade Metropolitana de Santos, Departamento de Neurologia, São Paulo SP, Brasil
,
Fabio Siquineli
19   Universidade Regional de Blumenau, Departamento de Neurologia, Blumenau SC, Brasil
,
Nise Alexandra de Carvalho Sousa
20   Universidade Hospital Getúlio Vargas, Departamento de Neurologia, Manaus AM, Brasil
,
Daniel Lima Varela
21   Serviço de Neurologia e Neurocirurgia de Passo Fundo, Passo Fundo RS, Brasil
,
Tereza Cristina Avila Winckler
22   Universidade Positivo, Departamento de Neurologia, Curitiba PR, Brasil
,
Yara Dadalti Fragoso
1   Universidade Metropolitana de Santos, Departamento de Neurologia, São Paulo SP, Brasil
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

ABSTRACT

Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.

RESUMO

As opções terapêuticas para esclerose múltipla (EM) modificaram-se ao longo dos últimos anos, trazendo uma nova categoria de drogas com melhor perfil de eficácia. No entanto, estas drogas vieram com um novo perfil de potenciais eventos adversos que exigem que o neurologista os reconheça bem e rapidamente. Uma das complicações mais temidas destes tratamentos para a EM é a leucoencefalopatia multifocal progressiva (LEMP), causada pela reativação do vírus John Cunningham (JCV). Objetivo: Identificar o perfil sorológico de JCV em pacientes com EM. Métodos: Dados sorológicos de JCV foram obtidos através do ensaio por enzimas imuno-adsorvidas (ELISA) fornecido pelo programa STRATIFY-JCV. Resultados: Um total de 1.501 testes sanguíneos foram obtidos de 1.102 pacientes com EM. O grupo teve 633 pacientes (57,1%) soropositivos para anticorpos anti-JCV e 469 pacientes negativos (42,9%). Vinte e três pacientes se tornaram posivitos após resultados iniciais negativos para anticorpos anti-JCV. A taxa de soroconversão foi 18,5% em 22 meses. Conclusão: O perfil sorológico do JCV e a soroconversão nos pacientes brasileiros foi semelhante àquela descrita em outros países.

Keywords:

multiple sclerosis - leukoencephalopathy, progressive multifocal - JC virus - natalizumab

Palavras-chave:

esclerose múltipla - leucoencefalopatia multifocal progressiva - vírus JC - natalizumab


Publikationsverlauf

Eingereicht: 04. Januar 2018

Angenommen: 30. Mai 2018

Artikel online veröffentlicht:
22. August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010 Apr;9(4):425-37. https://doi.org/10.1016/S1474-4422(10)70040-5
  • 2 Engels EA, Rollison DE, Hartge P, Baris D, Cerhan JR, Severson RK et al. Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer. 2005 Dec;117(6):1013-9. https://doi.org/10.1002/ijc.21277
  • 3 Tan CS, Ellis LC, Wüthrich C, Ngo L, Broge TA Jr, Saint-Aubyn J et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol. 2010 Sep;84(18):9200-9. https://doi.org/10.1128/JVI.00609-10
  • 4 Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol. 2006 Aug;60(2):162-73. https://doi.org/10.1002/ana.20933
  • 5 McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):117-25.
  • 6 Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018 May;17(5):467-80. https://doi.org/10.1016/S1474-4422(18)30040-1
  • 7 Grabowski MK, Viscidi RP, Margolick JB, Jacobson LP, Shah KV. Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients. J Med Virol. 2009 Jul;81(7):1140-50. https://doi.org/10.1002/jmv.21493
  • 8 Bellizzi A, Anzivino E, Rodio DM, Palamara AT, Nencioni L, Pietropaolo V. New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. Clin Dev Immunol. 2013;2013:839719. https://doi.org/10.1155/2013/839719
  • 9 Fragoso YD, Mendes MF, Arruda WO, Becker J, Brooks JB, Carvalho MJ et al. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive. Arq Neuropsiquiatr. 2013 Oct;71(10):780-2. https://doi.org/10.1590/0004-282X20130121
  • 10 Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol. 2014 Feb;21(2):299-304. https://doi.org/10.1111/ene.12304
  • 11 Paz SP, Branco L, Pereira MA, Spessotto C, Fragoso YD. Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica. Epidemiol Health. 2018 Jan;40:e2018001. https://doi.org/10.4178/epih.e2018001
  • 12 Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K et al. Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm. 2016 Jan;3(1):e195. https://doi.org/10.1212/NXI.20180083201800830195
  • 13 Outteryck O, Zéphir H, Salleron J, Ongagna JC, Etxeberria A, Collongues N et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler. 2014 Jun;20(7):822-9. https://doi.org/10.1177/1352458513505353
  • 14 Alroughani R, Akhtar S, Ahmed SF, Khoury SJ, Al-Hashel JY, Sahraian MA et al. JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study. J Neurol Sci. 2016 Jan;360:61-5. https://doi.org/10.1016/j.jns.2015.11.044
  • 15 Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL et al. High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol. 2016 Jun;23(6):1079-85. https://doi.org/10.1111/ene.12988
  • 16 Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L et al. Anti-JCV serology during natalizumab treatment: review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus seroconversion rates under natalizumab treatment and differences between technical and biological seroconverters. Mult Scler. 2018 Apr;24(5):563-73. https://doi.org/10.1177/1352458517728814
  • 17 Correia I, Jesus-Ribeiro J, Batista S, Martins AI, Nunes C, Macário MC, et al. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population. J Clin Neurosci. 2017 Nov;45:257-60. https://doi.org/10.1016/j.jocn.2017.08.006
  • 18 van Kempen ZL, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, et al. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients. Eur J Neurol. 2017 Sep;24(9):1196-9. https://doi.org/10.1111/ene.13355
  • 19 Peters J, Williamson E. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time. J Neurol. 2017 Dec;264(12):2409-12. https://doi.org/10.1007/s00415-017-8643-4
  • 20 Alroughani R, Akhtar S, Ahmed S, Al-Hashel J. A longitudinal study of JC virus serostatus stability among multiple sclerosis patients. Mult Scler Relat Disord. 2018 Feb;20:132-5. https://doi.org/10.1016/j.msard.2018.01.016
  • 21 Hegen H, Auer M, Bsteh G, Di Pauli F, Plavina T, Walde J, et al. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. PLoS One. 2017 Mar;12(3):e0174005. https://doi.org/10.1371/journal.pone.0174005